These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1250 related items for PubMed ID: 22766983

  • 1. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
    Chang SJ, Bristow RE, Ryu HS.
    Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
    [Abstract] [Full Text] [Related]

  • 2. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
    Bamias A, Bamia C, Zagouri F, Kostouros E, Kakoyianni K, Rodolakis A, Vlahos G, Haidopoulos D, Thomakos N, Antsaklis A, Dimopoulos MA.
    Oncology; 2013 Dec; 84(3):158-65. PubMed ID: 23296063
    [Abstract] [Full Text] [Related]

  • 3. Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation.
    Fotopoulou C, Zang R, Gultekin M, Cibula D, Ayhan A, Liu D, Richter R, Braicu I, Mahner S, Harter P, Trillsch F, Kumar S, Peiretti M, Dowdy SC, Maggioni A, Trope C, Sehouli J.
    Ann Surg Oncol; 2013 Apr; 20(4):1348-54. PubMed ID: 23054114
    [Abstract] [Full Text] [Related]

  • 4. Role of neoadjuvant chemotherapy in the management of advanced ovarian cancer.
    Zhao D, Wu LY, Wang XB, Li XG.
    Asian Pac J Cancer Prev; 2015 Apr; 16(6):2369-73. PubMed ID: 25824766
    [Abstract] [Full Text] [Related]

  • 5. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Winter WE, Maxwell GL, Tian C, Sundborg MJ, Rose GS, Rose PG, Rubin SC, Muggia F, McGuire WP, Gynecologic Oncology Group.
    J Clin Oncol; 2008 Jan 01; 26(1):83-9. PubMed ID: 18025437
    [Abstract] [Full Text] [Related]

  • 6. Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a Retrospective French Multicentric Study.
    Luyckx M, Leblanc E, Filleron T, Morice P, Darai E, Classe JM, Ferron G, Stoeckle E, Pomel C, Vinet B, Chereau E, Bergzoll C, Querleu D.
    Int J Gynecol Cancer; 2012 Oct 01; 22(8):1337-43. PubMed ID: 22964527
    [Abstract] [Full Text] [Related]

  • 7. Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer.
    Chang SJ, Bristow RE, Ryu HS.
    Gynecol Oncol; 2012 Sep 01; 126(3):381-6. PubMed ID: 22609747
    [Abstract] [Full Text] [Related]

  • 8. "The impact of debulking surgery in patients with node-positive epithelial ovarian cancer: Analysis of prognostic factors related to overall survival and progression-free survival after an extended long-term follow-up period".
    Pereira A, Pérez-Medina T, Magrina JF, Magtibay PM, Rodríguez-Tapia A, Cuesta-Guardiola T, Peregrin I, Mendizabal E, Lizarraga S, Ortiz-Quintana L.
    Surg Oncol; 2016 Mar 01; 25(1):49-59. PubMed ID: 26979641
    [Abstract] [Full Text] [Related]

  • 9. Primary chemotherapy for inoperable ovarian, fallopian tube, or primary peritoneal cancer with or without delayed debulking surgery.
    Saha A, Varughese M, Gallagher CJ, Orphanos G, Wilson P, Oram D, Jeyarajah A, Reynolds K, Shepherd J, McCormack M, Olaitan A, McDonald N, Mould T, McNeish I, Ledermann JA.
    Int J Gynecol Cancer; 2012 May 01; 22(4):566-72. PubMed ID: 22426404
    [Abstract] [Full Text] [Related]

  • 10. Prognostic impact of additional extended surgical procedures in advanced-stage primary ovarian cancer.
    Kommoss S, Rochon J, Harter P, Heitz F, Grabowski JP, Ewald-Riegler N, Haberstroh M, Neunhoeffer T, Barinoff J, Gomez R, Traut A, du Bois A.
    Ann Surg Oncol; 2010 Jan 01; 17(1):279-86. PubMed ID: 19898901
    [Abstract] [Full Text] [Related]

  • 11. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.
    Chan JK, Tian C, Monk BJ, Herzog T, Kapp DS, Bell J, Young RC, Gynecologic Oncology Group.
    Cancer; 2008 May 15; 112(10):2202-10. PubMed ID: 18348296
    [Abstract] [Full Text] [Related]

  • 12. Clinical outcome of tertiary surgical cytoreduction in patients with recurrent epithelial ovarian cancer.
    Fotopoulou C, Richter R, Braicu IE, Schmidt SC, Neuhaus P, Lichtenegger W, Sehouli J.
    Ann Surg Oncol; 2011 Jan 15; 18(1):49-57. PubMed ID: 20697821
    [Abstract] [Full Text] [Related]

  • 13. Treatment of microscopic disease with hyperthermic intraoperative intraperitoneal chemotherapy after complete cytoreduction improves disease-free survival in patients with stage IIIC/IV ovarian cancer.
    Cascales-Campos PA, Gil J, Gil E, Feliciangeli E, González-Gil A, Parrilla JJ, Parrilla P.
    Ann Surg Oncol; 2014 Jul 15; 21(7):2383-9. PubMed ID: 24599409
    [Abstract] [Full Text] [Related]

  • 14. Prognostic significance of postoperative morbidities in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy and delayed primary surgical debulking.
    Le T, Alshaikh G, Hopkins L, Faught W, Fung MF.
    Ann Surg Oncol; 2006 Dec 15; 13(12):1711-6. PubMed ID: 17009146
    [Abstract] [Full Text] [Related]

  • 15. Long-term survival in advanced ovarian carcinoma following cytoreductive surgery with standard peritonectomy procedures.
    Tentes AA, Mirelis CG, Markakidis SK, Bekiaridou KA, Bougioukas IG, Xanthoulis AI, Tsalkidou EG, Zafiropoulos GH, Nikas IH.
    Int J Gynecol Cancer; 2006 Dec 15; 16(2):490-5. PubMed ID: 16681716
    [Abstract] [Full Text] [Related]

  • 16. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
    Tu H, Huang H, Huang QD, Li Z, Feng YL, Liu JH.
    Zhonghua Fu Chan Ke Za Zhi; 2012 Dec 15; 47(12):928-33. PubMed ID: 23324194
    [Abstract] [Full Text] [Related]

  • 17. Progress in survival outcomes in patients with advanced ovarian cancer treated by neo-adjuvant platinum/taxane-based chemotherapy and late interval debulking surgery.
    Stoeckle E, Bourdarias L, Guyon F, Croce S, Brouste V, Thomas L, Floquet A.
    Ann Surg Oncol; 2014 Feb 15; 21(2):629-36. PubMed ID: 24052318
    [Abstract] [Full Text] [Related]

  • 18. Multiple Cycles of Neoadjuvant Chemotherapy Associated With Poor Survival in Bulky Stage IIIC and IV Ovarian Cancer.
    Ren Y, Shi T, Jiang R, Yin S, Wang P, Zang R.
    Int J Gynecol Cancer; 2015 Oct 15; 25(8):1398-404. PubMed ID: 26222486
    [Abstract] [Full Text] [Related]

  • 19. Lymph Node Involvement Pattern and Survival Differences of FIGO IIIC and FIGO IIIA1 Ovarian Cancer Patients After Primary Complete Tumor Debulking Surgery: A 10-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network.
    Gasimli K, Braicu EI, Nassir M, Richter R, Babayeva A, Chekerov R, Darb-Esfahani S, Sehouli J, Muallem MZ.
    Ann Surg Oncol; 2016 Apr 15; 23(4):1279-86. PubMed ID: 26832880
    [Abstract] [Full Text] [Related]

  • 20. Is neo-adjuvant chemotherapy a "waiver" of extensive upper abdominal surgery in advanced epithelial ovarian cancer?
    Kang S, Jong YH, Hwang JH, Lim MC, Seo SS, Yoo CW, Park SY.
    Ann Surg Oncol; 2011 Dec 15; 18(13):3824-7. PubMed ID: 21691879
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 63.